NICE TA463 - for previously treated advanced renal cell cancer in adults following prior vascular endothelial growth factor targeted therapy. (Decision date - September 2017).
NICE TA516: for treating medullary thyroid cancer. (Decision date - April 2018).
NICE TA542: for untreated advanced renal cell carcinoma. (Decision date - November 2018).
NICE TA849: for previously treated advanced hepatocellular carcinoma. (Decision date - January 2023)
DNP:
NICE TA928: Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine- Not recommended (Decision - December 2023)
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
